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ARTICLE
Unravelling the immune signature of Plasmodium
falciparum transmission-reducing immunity
Will J.R. Stone1,2, Joseph J. Campo3, André Lin Ouédraogo4, Lisette Meerstein-Kessel1, Isabelle Morlais5,6,
Dari Da7, Anna Cohuet 6,7, Sandrine Nsango5,8, Colin J. Sutherland2, Marga van de Vegte-Bolmer9,
Rianne Siebelink-Stoter9, Geert-Jan van Gemert9, Wouter Graumans9, Kjerstin Lanke9, Adam D. Shandling3,
Jozelyn V. Pablo3, Andy A. Teng3, Sophie Jones2, Roos M. de Jong9, Amanda Fabra-García9, John Bradley10,
Will Roeffen9, Edwin Lasonder11, Giuliana Gremo12, Evelin Schwarzer 12, Chris J. Janse13, Susheel K. Singh14,15,
Michael Theisen14,15, Phil Felgner16, Matthias Marti17,18, Chris Drakeley2, Robert Sauerwein1,
Teun Bousema1,2 & Matthijs M. Jore9
Infection with Plasmodium can elicit antibodies that inhibit parasite survival in the mosquito,
when they are ingested in an infectious blood meal. Here, we determine the transmission-
reducing activity (TRA) of naturally acquired antibodies from 648 malaria-exposed indivi-
duals using lab-based mosquito-feeding assays. Transmission inhibition is significantly
associated with antibody responses to Pfs48/45, Pfs230, and to 43 novel gametocyte pro-
teins assessed by protein microarray. In field-based mosquito-feeding assays the likelihood
and rate of mosquito infection are significantly lower for individuals reactive to Pfs48/45,
Pfs230 or to combinations of the novel TRA-associated proteins. We also show that naturally
acquired purified antibodies against key transmission-blocking epitopes of Pfs48/45 and
Pfs230 are mechanistically involved in TRA, whereas sera depleted of these antibodies retain
high-level, complement-independent TRA. Our analysis demonstrates that host antibody
responses to gametocyte proteins are associated with reduced malaria transmission effi-
ciency from humans to mosquitoes.
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P lasmodium gametocytes develop from their asexual pro-genitors and are the only malaria parasite life-stage infectiveto mosquitoes. In preparation for their development in the
mosquito, gametocytes cease to express many proteins involved
in the parasites cycle of asexual replication, and upregulate others
that are involved in sexual development1,2. Some of these have
essential roles in mosquito-stage development3,4, which culmi-
nates in the insect becoming infectious to humans.
In surveys where mosquitoes were fed directly on the skin or
on a blood sample, it was noted that some gametocytaemic
individuals including those with high gametocyte densities were
not infectious5,6. This may be associated with naturally acquired
antibodies that interfere with parasite development within mos-
quitoes to reduce or prevent mosquito infection7,8. The role of
antibodies in determining transmission efficiency can be tested in
mosquito-feeding assays, in which purified antibodies are added
to a mosquito blood meal that contains gametocytes9,10. Evidence
for naturally acquired transmission-reducing activity (TRA) is
provided if test antibodies in endemic serum cause a reduction in
the number of developing Plasmodium oocysts relative to mos-
quitoes fed the same infectious blood meal without test anti-
bodies. TRA can be experimentally induced after immunisation of
animals with inactivated Plasmodium gametocytes or gametes8,11.
The gametocyte and gamete proteins P48/45 and P230 have been
identified as targets of transmission-blocking monoclonal anti-
bodies (mAb), which act by inhibiting the protein’s role in gamete
fertilisation in the mosquito gut3,4,12. Monoclonal antibodies
specific to the zygote and ookinete proteins P25 and P28 were
also shown to block transmission, by inhibiting ookinete invasion
of the midgut epithelium13. All four have been produced as
recombinant proteins that can induce antibody-mediated TRA in
animal models13–15.
Because P25 and P28 mRNA is translationally repressed until
zygote formation16, antibodies specific to these proteins appear
absent in endemic populations17,18. In contrast, responses to P48/
45 and P230 are commonly observed in naturally infected
individuals10,19,20. The presence of antibodies to Plasmodium
falciparum Pfs48/45 and Pfs230 in endemic sera has been asso-
ciated with TRA in several, but not all sero-epidemiological
surveys10,21–28. Importantly, many individuals with functional
TRA do not have measurable antibodies against these two
proteins10,23,25,28–31. Despite these observations, there has been
no attempt to demonstrate the contribution of naturally acquired
α-Pfs48/45 and α-Pfs230 antibodies to transmission inhibition,
and little investigation of alternative targets of natural TRA. The
gametocyte proteome has now been described in detail32,33.
Utilising the protein microarray platform, genome scale data sets
have been combined with functional and immunological data to
provide valuable insight into mechanisms and markers of malaria
humoral immunity34,35.
Here, we aim to investigate the immune signature of naturally
occurring antibody-mediated TRA, to expand and prioritise
antigenic targets for functional characterisation as biomarkers, or
transmission-blocking vaccine candidates. To this purpose, we
utilise a protein microarray comprising an inclusive selection of
proteins expressed during gametocyte development. We assess
antibody responses to these proteins and to correctly folded
Pfs48/4536 and Pfs23015 in 648 malaria-exposed individuals from
Burkina Faso, the Gambia, Cameroon, and from migrants from
the Netherlands. Using purified total IgG, we assess the functional
TRA of antibodies from the same individuals by determining
their effect on mosquito infection density in standard membrane-
feeding assays (SMFA) with cultured P. falciparum gametocytes
and Anopheles stephensi mosquitoes. Our analysis reveals sig-
nificant associations between high-level TRA and responses to
Pfs48/45, Pfs230 and 43 novel gametocyte proteins. For a subset
of 366 gametocyte-positive donors who had provided blood
samples to Anopheles gambiae s.s. or An. coluzzii mosquitoes in
field-based membrane-feeding assays, we determine the associa-
tion of these antibody responses with mosquito infection rates
during natural infections. For Pfs48/45 and Pfs230, we provide
functional data that demonstrate their role in natural TRA. For
one of the newly identified proteins (PfGEST), we provide
experimental data that does not support its functional role in
natural TRA.
Results
Antibody responses to gametocyte antigens. Plasma was col-
lected in epidemiological studies in Burkina Faso37–41,
Cameroon42,43 and the Gambia24,44–48, as well as from Dutch
migrants who had lived for several years in malaria-endemic areas
and reported repeated malaria episodes (Table 1). Individuals
from malaria-endemic areas were all asymptomatic when sam-
pled, and were either recruited randomly from the community (n
= 42), or based on the observation of malaria parasites (n = 273)
or specifically gametocytes (n = 276) in blood smears. For a
selection of individuals from malaria-endemic areas (n = 498),
infectivity to mosquitoes at the moment of sample collection was
determined by offering a venous blood sample to Anopheles
gambiae s.s. or An. coluzzii in a direct membrane-feeding assay
(DMFA) (Table 1). Dutch migrants had no DMFA performed
and had either recently returned from extended periods in
endemic areas (within 6 months after return; n = 8) or had
returned more than a year before sampling (n = 49). Those who
had returned more than a year before sampling had lived in areas
with endemic P. falciparum transmission for longer than 15 years,
Table 1 Sample characteristics
Sample origin
(study reference)
Samples
(n)
Age
(median, range)
Asexual positive
(%)
Gametocyte-positive
(%)
Parasite free
(%)
Infectious
(DMFA, %)
TR activity
<10% ≥50% ≥80% ≥90%
Gambia24, 44–48 226 5.0
(1.0–17.0)
99.1%
(224/226)
74.2%
(167/225)
0.4%
(1/226)
24.0%
(44/183)
54.0%
(122/226)
15.9%
(36/226)
4.4%
(10/226)
3.1%
(7/226)
Burkina Faso24, 44–48 225 16.0
(1.8–74.0)
56.5%
(109/193)
53.5%
(114/213)
31.9%
(68/213)
45.5%
(86/189)
68.4%
(154/225)
8.0%
(18/225)
2.7%
(6/225)
1.8%
(4/225)
Cameroon42, 43 140 8.5
(5.0–16.0)
90.5%
(117/133)
93.5%
(137/138)
0.0%
(0/139)
73.8%
(93/126)
68.6%
(96/140)
14.3%
(20/140)
6.4%
(9/140)
4.3%
(6/140)
The Netherlands37–39, 43 57 79.5
(26.0–84.0)
3.9%
(2/51)
3.9%
(2/51)
96.1%
(49/51)
— 57.9%
(33/57)
17.5%
(10/57)
8.8%
(5/57)
8.8%
(5/57)
Combined 649 7.1
(1–92)
75.6%
(458/606)
65.8%
(413/628)
18.8%
(118/629)
44.8%
(223/498)
62.5%
(405/648)
13.0%
(84/648)
4.6%
(30/648)
3.4%
(22/649)
“—” data unavailable, or untested; TR activity (%): percent transmission-reducing (TR) activity of purified IgG in the standard membrane-feeding assay (SMFA), relative to control mosquitoes fed the
same gametocyte batch without test antibodies. TR activity is the mean of two independent SMFA runs for all samples with ≥80% TR activity in the first run, Samples: total number of samples with TR
activity assessed in the SMFA, Asex/Gct %: asexual parasite and gametocyte prevalence by microscopy at the time of sampling, for individuals with available data, Parasite free %: no asexual parasites or
gametocytes observed by microscopy
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and reported between 2 and >80 clinical malaria episodes during
that time.
Antibody responses to Pfs48/45 (Pfs48/45-10C36) and Pfs230
(230CMB15) were determined by enzyme-linked immunosorbent
assay (ELISA) using recombinant, correctly folded proteins. A
protein microarray was constructed to assess responses to other
gametocyte antigens. This array included a total of 315 proteins
(Supplementary Data 1) that were broken up into 528 over-
lapping fragments <1000 amino acids in length (overlaps of 17
amino acids) for protein expression in an Escherichia coli based
in vitro transcription–translation (IVTT) system49,50. Antigens
on the array included proteins previously implicated as eliciting
TRA after immunisation, proteins involved in early gametocyte
development as possible markers of gametocyte exposure1,
markers of asexual parasite exposure51 and proteins expressed
in gametocytes based on recent proteomic analysis52. To ensure
that the array included most potential antibody targets involved
in TRA, we preferentially included proteins that had transmem-
brane domains, signal peptides or GPI anchors. Specificity of
proteins to gametocytes was not a prerequisite for inclusion on
the array, however 228/315 proteins had consensus evidence for
enrichment in gametocytes based on a recent integration analysis
of 11 available proteomics data sets53 (Supplementary Data 1).
Among donors from malaria-endemic regions, the prevalence
and magnitude of antibody responses to Pfs48/45 and Pfs230
increased with age (Fig. 1a–d). In contrast, the overall breadth
(linear regression (LinR): p< 0.001) and magnitude (analysis of
variance (ANOVA): p = 0.013) of response to antigens on the
microarray decreased with age (Fig. 1e, f). The same associations
were observed when analyses were restricted to donors from
p<0.001
p<0.001 p<0.001 p=0.013
p<0.001
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Fig. 1 Antibody responses to Pfs48/45, Pfs230 and to the microarray proteins with age. Antibody responses to correctly folded, recombinant Pfs48/45-
10C and Pfs230 (230CMB) were measured using ELISA, with antibody intensity given as the ELISA optical density (OD) values (450 nm). Antibody
responses to microarray proteins are given as the log2-transformed signal intensity (SI) minus the vehicle SI, which equates to the log2-fold change over
this background. All graphs show only individuals from endemic areas (Dutch migrants excluded). Sample size: 0–5= 131, 5–15= 366, 15+= 71. a, c Bars
show the seroprevalence of α-Pfs48/45 and α-Pfs230 antibodies with age, with Clopper–Pearson confidence intervals. b, d Boxplots showing α-Pfs48/45
and α-Pfs230 antibody intensity with age. e Boxplots showing responses to the microarray protein targets (n= 528). Antibody breadth is the number of
proteins reactive above background in each individual, within the given groups. f Magnitude of antibody response to microarray protein targets. Each dot
represents the average SI of response to each protein target by all individuals within given groups. p-values for prevalence data are from likelihood ratio test
for differences in seroprevalence between all age groups, derived from logistic regression and adjusted for gametocyte density. p-values for intensity data
and response breadth are from an F-test for differences in OD/SI between all age groups, derived from linear regression and adjusted for gametocyte
density or from ANOVA (for magnitude only). For all boxplots, outliers are shown in black, whereas all data points are shown in grey as a bee-swarm
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Burkina Faso (n = 225), the site with the widest age range of
donors (Supplementary Fig. 1).
Antibody responses and transmission-reducing activity (TRA).
To assess functional TRA, IgG was purified from the sera of all
648 individuals and provided to Anopheles stephensi mosquitoes
together with a blood meal containing cultured NF54 or trans-
genic NF54HT-GFP-Luc gametocytes in standard membrane-
feeding assays (SMFA)9,54. If the donor IgG caused ≥80%
reduction in oocyst formation relative to control mosquitoes
(TRA ≥80%), the SMFA was repeated with separate gametocyte
culture material. In total, 3.3% (22/648) of the antibody samples
caused replicable TRA of ≥90% (Table 1). On a continuous scale,
TRA decreased with age, but was not significantly associated with
gametocyte density at the point of sampling (LinR: p = 0.269)
(Supplementary Fig. 2). Because previous gametocyte exposure is
associated with TRA28, comparisons between sub-groups were
nevertheless adjusted for gametocyte density. Though inter-
mediate TRA may be relevant for transmission there are uncer-
tainties about its reliable measurement in the SMFA55,56. TRA
was therefore dichotomised into ≥90% (high-level TRA) and
<10% TRA (no TRA) before assessing associations with antibody
responses. The group without evidence for TRA was refined by
excluding individuals without microscopically detectable game-
tocyte densities at the time of sampling, resulting in 22 indivi-
duals with high-level TRA activity and 254 individuals who were
exposed to gametocytes (and thus likely to respond to gametocyte
antigens) but showed no evidence for TRA. Using these two
categories, high-level TRA was significantly more likely in indi-
viduals seropositive for α-Pfs230 (odds-ratio (OR) from logistic
regression (LogR) 7.9 (95% confidence interval (CI): 2.8–22.8), p
< 0.001), α-Pfs48/45 (OR 4.4 (95% CI: 1.5–12.9), p = 0.007) or
either antigen (OR 5.90 (95% CI: 2.1–16.7), p = 0.001) (Supple-
mentary Table 1, Supplementary Data 2). Antibody density was
also higher for Pfs230 (LinR: p< 0.001) and Pfs48/45 (p< 0.001)
in individuals exhibiting high-level TRA (Fig. 2a, b; Supplemen-
tary Data 2).
In addition to Pfs230 and Pfs48/45, the average magnitude of
response to each microarray target was also higher in individuals
with high-level TRA (students t-test: p = 0.012) (Fig. 2d), whilst
the breadth of response by each individual was not statistically
significantly different between individuals with high-level TRA
p=0.05
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Fig. 2 Transmission-reducing activity (TRA) and antibody responses to Pfs48/45, Pfs230 and microarray proteins. TRA was categorised as described, to
compare responses between gametocyte-positive individuals with <10% TRA, and individuals with >90% TRA. Antibody responses to correctly folded,
recombinant Pfs48/45-10C and Pfs230 (230CMB) were measured using ELISA, with antibody intensity given as the ELISA optical density (OD) values
(450 nm). Antibody responses to microarray proteins are given as the log2-transformed signal intensity (SI) minus the vehicle SI, which equates to the
log2-fold change over this background. a, b Boxplots of α-Pfs48/45 and α-Pfs230 antibody intensity with TRA. c Responses to the microarray protein
targets (n= 528). Antibody breadth is the number of proteins reactive above background in each individual, within the given groups. d Magnitude of
antibody response to microarray protein targets. Each dot represents the average SI of response to each protein target by all individuals within given
groups. p-values for intensity data and response breadth are from an F-test for differences in OD/SI between all age groups, derived from linear regression,
and adjusted for gametocyte density or from students t-test (for magnitude only). For all boxplots, outliers are shown in black, whereas all data points are
shown in grey as a bee-swarm. e Volcano plot showing the log2-fold change of the mean signal intensity for TRA as defined above. The p-value shown by
the dotted line is unadjusted for false discovery. Black-circled data points are those that remain significant after p-values have been adjusted to control the
rate of false discovery below 5%, using the Benjamini–Hochberg method
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compared to those with no evidence of TRA (LinR: p = 0.89)
(Fig. 2c). Sixty microarray proteins had statistically significantly
higher antibody magnitude in individuals with high-level TRA,
after p-values had been adjusted to control the false discovery rate
(FDR) (Fig. 2e)57. The inverse, higher responses in individuals
with no TRA, was not observed (Supplementary Data 3). Logistic
regression models with FDR controlled p-values showed that
antibody prevalence to 27 microarray targets was significantly
associated with high-level TRA, 25 of which were also
significantly more reactive in the analysis of signal intensity.
Because large proteins were fragmented on the array, the
combined list of 62 novel microarray targets with TRA-
associated antibody responses in either the linear (response
intensity) or logistic (response prevalence) analysis represented
fragments of 43 unique proteins (Supplementary Data 2). 15 of
the 43 proteins with TRA-associated responses are conserved
unknown proteins. Two are known gametocyte/gamete proteins
with putative roles in gamete egress; PF3D7_1038400 (gameto-
cyte-specific protein, Pf11-1) and PF3D7_1449000 (gamete
surface and sporozoite traversal protein/GEST).
TRA-associated responses on the array showed only partial
overlap with Pfs48/45 and Pfs230 responses. Individuals with
high-level TRA who were seronegative for both α-Pfs230 and α-
Pfs48/45 (n = 10/22), had antibody responses to significantly
more TRA-associated microarray targets (median breadth 11 (out
of 62) (interquartile range (IQR) 3–26)) than gametocyte-positive
individuals without TRA (n = 211; median breadth 4 (out of 62)
(IQR 2–9), LinR: p = 0.018). Responses to some TRA biomarkers
were highly prevalent in individuals with high-level TRA who
lacked significant responses to Pfs45/45 and Pfs230 (e.g. Pf11-1
(PF3D7_103840) = 70% (n/N = 7/10); LSA3 (PF3D7_0220000) =
80% (n/N = 8/10)). Responses to one target protein mapping to
PF3D7_1103800 (CCR4-NOT) were present in 60% (n/N = 6/10)
of high-level TRA α-Pfs48/45 and α-Pfs230 seronegatives,
whereas seroprevalence for this target in individuals with no
TRA was 10.3% (n/N = 26/254) (Supplementary Data 4).
Interestingly, 10 of the 43 proteins with TRA-associated
antibody responses are putatively exported during early gameto-
genesis1. Though the majority of these proteins are enriched in
asexual parasites, their association with TRA may reflect previous
observations that TR immunity is induced and wanes rapidly
after gametocyte exposure26,27. Responses to putative markers of
asexual parasite exposure (PF3D7_1036000 (Merozoite surface
protein 11 (MSP11)), PF3D7_0711700 (erythrocyte membrane
protein 1, PfEMP1 (VAR)), PF3D7_0731600 (acyl-CoA synthe-
tase (ACS5)), and PF3D7_0423700 (early-transcribed membrane
protein 4 (ETRAMP4))51 were not associated with TRA, either in
terms of response intensity (Bayes empirical t-test: FDR-adjusted
p = 0.34–0.99) or seroprevalence (LogR: FDR-adjusted p = 1).
TRA and mosquito infection rate in natural infections. Next,
we determined whether the immune profile associated with TRA
in the SMFA was also associated with mosquito infection rates
observed in direct membrane-feeding experiments. Data on the
infectivity of donor blood samples to mosquitoes at the time of
plasma donation was available for 494 individuals for whom
gametocyte status had been assessed by microscopy and TRA
assessed in the SMFA. Of the 128 individuals without patent
gametocytaemia, 18 (14.1%) were infective to mosquitoes in the
DMFA. Of the 366 gametocyte-positive individuals, 203 (55.5%)
infected at least one mosquito, with a median mosquito infection
rate of 20% (IQR 7.7–42.5%). There was good agreement between
transmission outcomes in the SMFA using cultured gametocytes
and An. stephensi mosquitoes, and the field-based DMFA using
gametocytes in infected individuals and An. gambiae s.s. or An.
coluzzii mosquitoes; Individuals with high-level TRA in the
SMFA were significantly less likely to infect any mosquitoes in the
DMFA (LogR: OR 0.23 (95% CI: 0.06–0.79), p = 0.020), and more
likely to do so at a reduced rate (OR 0.10 (95% CI: 0.2–0.61), p =
0.012). The likelihood of gametocyte-positive individuals infect-
ing any mosquitoes in the DMFA was significantly lower if ser-
opositive for Pfs230 (LogR: OR 0.42 (95% CI: 0.22–0.78), p =
0.006), Pfs48/45 (OR 0.30 (95% CI: 0.16–0.59), p< 0.001), or
either or both antigens (OR 0.33 (95% CI: 0.19–0.58), p< 0.001)
(Fig. 3a). The proportion of mosquitoes that became infected after
feeding was also significantly lower for individuals seropositive
for Pfs230 (LogR: OR 0.36 (95% CI: 0.14–0.88), p< 0.027), Pfs48/
45 (OR 0.14 (95% CI: 0.05–0.40), p< 0.001) or either or both
antigens (OR 0.25 (95% CI: 0.11–0.55), p = 0.001) (Fig. 3b). The
proportion of mosquitoes that became infected decreased with
increasing Pfs230 antibody density (LogR: OR for an increase of
0.1 normalised optical density 0.59 (95% CI: 0.40–0.86), p =
0.007) and Pfs48/45 antibody density (OR 0.43 (95% CI:
0.28–0.66), p< 0.001).
Mosquito infection prevalence was lower in gametocyte-
positive individuals with antibodies recognising more of the 62
novel protein microarray targets with TRA-associated antibody
responses (Supplementary Fig. 3). Individuals responding to ≥14/
62 microarray proteins (14 being the 75th percentile of breadth of
response to these targets) were significantly less likely to infect
mosquitoes (LogR: OR 0.31 (95% CI: 0.18–0.51), p< 0.001), and
more likely to do so at a reduced rate (OR 0.21 (95% CI:
0.09–0.45). p< 0.001) (Fig. 3a, b). After excluding Pfs48/45 or
Pfs230 seropositive individuals, infectiousness and infection rate
remained significantly lower in individuals responding to ≥14 of
the 62 TRA-associated microarray proteins (infectiousness: LogR,
OR 0.29 (95% CI: 0.16–0.53), p< 0.001, infection rate: OR 0.23
(95% CI: 0.10–0.52), p< 0.001).
Functional involvement of antibodies in TRA. To demonstrate
whether naturally acquired antibodies to Pfs230 or Pfs48/45 were
causally associated with TRA, we affinity-purified antibodies
specific to key transmission-blocking epitopes of these proteins
and assessed their activity in the SMFA (Table 2). These experi-
ments were performed for 6 donors whose IgG showed high-level
TRA and for whom high volumes of plasma (≥1 mL) were
available; 3 of these donors had ≥10 mL plasma available,
allowing additional testing after 9-fold antibody concentration of
IgG. The flow-through of affinity purification experiments,
depleted of α-Pfs230 and α-Pfs48/45 antibodies, was also tested in
the SMFA to quantify TRA of antibodies to other target antigens.
Concentrated back to the original plasma volume, α-Pfs48/45
antibodies of one donor independently inhibited transmission
(TRA 91.5% (95% CI: 86.4–94.7)), whereas α-Pfs230 antibodies of
a different donor had low but statistically significant TRA (TRA
41.1% (95% CI: 15.5–60.4)). When antibodies were concentrated
to nine times their physiological concentration, α-Pfs48/45 anti-
bodies from one additional individual, and α-Pfs230 antibodies
from two additional individuals significantly reduced transmis-
sion to mosquitoes (Pfs48/45: TRA 81.3%, (95% CI: 70.9–88.0),
Pfs230: TRA 94.8% (95% CI: 90.2–97.3) & 99.3% (95%
98.6–99.6), Table 2). For all individuals the α-Pfs48/45 and α-
Pfs230-depleted IgG (containing no antibodies against Pfs48-45
epitopes 1–3, or Pfs230 epitope C, confirmed by ELISA) inhibited
transmission to mosquitoes (Table 2). This activity was
complement-independent.
To determine the presence of naturally acquired antibodies
binding to unknown gamete surface antigens, we performed
surface immuno-fluorescence assays (SIFA) using gametes of a
Pfs48/45 knockout (KO) parasite3 that does not produce surface
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retained Pfs23012. Pfs48/45- and Pfs230-specific antibodies
confirmed the absence of these proteins on Pfs48/45 KO gamete
surfaces (Fig. 4). The immuno-fluorescence of gamete surfaces
observed using total IgG and IgG depleted of α-Pfs48/45 and α-
Pfs230 antibodies from naturally exposed individuals therefore
reflects recognition of unknown antigens on the gamete surface
(Fig. 4; Supplementary Fig. 5A).
Antibody responses to a number of the 43 novel proteins that
are associated with TRA (Supplementary Data 2) may be
biomarkers of high prior gametocyte exposure rather than
causally related to TRA. We thus curated this list of proteins by
excluding genes with known or predicted intracellular products,
while retaining genes based on evidence for a role in transmission
reduction or gamete viability, or predicted compatibility with
gametocyte/gamete surface expression. In addition to Pfs230 and
Pfs48/45, 13 novel proteins possess sequence characteristics that
are compatible with surface expression or have known roles in
gamete viability (Table 3; Supplementary Data 5) and may thus
form biologically plausible targets of transmission-inhibiting
antibodies. mAbs specific to Pf11-1, one of the biomarkers with
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Fig. 3 Seroprevalence to Pfs48/45, Pfs230, and novel TRA-associated microarray proteins, and infectiousness in the direct membrane-feeding assay
(DMFA). Individuals with DMFA data were categorised according to their possession of antibodies specific to: Pfs48/45 (positive (+)/negative (−));
Pfs230 (positive (+)/negative (−)); ≥14 of the 61 novel microarray proteins with TRA-associated antibody responses (14 being the 75th percentile of the
breadth of response to these microarray targets among the entire sample set); ≥4 of the 16 novel microarray proteins with TRA-associated antibody
responses that are also plausible targets of antibodies with TRA (4 being the 75th percentile of the breadth of response to these microarray targets among
the entire sample set). a Bars show the proportion of infectious individuals among seropositive/seronegative gametocytaemic individuals with DMFA data,
with Clopper–Pearson confidence intervals. n/N= number of individuals seropositive/total number of individuals with DMFA data. P-values are from
logistic regression, with adjustment for gametocyte density. b Boxplots show the percentage of mosquitoes that became infected after feeding. n/N= the
number of mosquitoes feeding on seropositive individuals/the total number of mosquitoes feeding on individuals with DMFA data. p-values are from
logistic models, adjusted for gametocyte density and with host (individual the mosquitoes were feeding upon) as a random effect. For all boxplots, outliers
are shown as hollow black circles, whereas all data points are shown as solid coloured circles
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a role in gamete egress, were shown previously to reduce
transmission to mosquitoes in membrane-feeding experiments58.
Previous data show that the P. berghei homologue of another of
our markers, PF3D7_1449000 (PfGEST), shows partial
association with gamete surfaces and has a clear role in gamete
egress59. We tested three monoclonal antibodies (mAb) against
PfGEST in the SIFA and SMFA. SIFA with PfGEST mAbs
showed no, or very limited surface reactivity, indicating that
Table 2 Activity of affinity-purified antibodies against R0.10C (Pfs48/45) and 230CMB (Pfs230) from transmission-reducing
sera
ID Location Sex/
age
Time since
malaria
exposure
TRA% (95% confidence intervals)
1. Total
IgG
2a. R0.10C
IgG
2b. R0.10C
IgG (conc.)
3. Total
IgG w/o
R0.10c IgG
4a. 230CMB
IgG
4b.
230CMB
IgG (conc.)
5a. Total IgG w/
o R0.10C &
230CMB IgG
5b. Total IgG
w/o R0.10C &
230CMB IgG (C−)
A Netherlands M/69 Infected 99.4
(98.9–99.7)
91.5
(86.4–94.7)
ND 99.5
(99–99.7)
−2.5*
(−38.6–24.2)
99.3
(98.6–99.6)
99.5
(99–99.8)
99.8
(99.5–99.9)
B Netherlands — Infected 99.6
(99.3–99.8)
−42.8
(−80.5–12.9)
ND 96.7
(95.6–97.5)
−15.7*
(−46.1–8.4)
ND 88.5
(85.7–90.7)
87
(79.9–91.6)
C Netherlands — <6months 99.9
(99.7–100)
25.6*
(−4.1–46.8)
81.3
(70.9–88)
99.4
(99–99.7)
42.1
(15.5–60.4)
94.8
(90.2–97.3)
89.1
(80.2–94)
95.8
(91.4–98)
D Netherlands M/74 ~5 years 99.6
(99–99.8)
−14.7*
(−65.3–20.5)
−0.3*
(−38.7–27.4)
85.4
(75.4–91.3)
32*
(−1–54.1)
0.1*
(−58.8–37.1)
71.8
(52.7–83.2)
80.8
(66.8–88.9)
E Cameroon F/12 Infected 98.8
(98–99.3)
41.7
(26–54.1)
ND 93.1
(90.3–95.1)
16.5*
(−8.6–35.8)
ND 92.8
(89–95.3)
93.4
(88.6–96.1)
F Cameroon F/6 Infected 100
(99.8–100)
29.3*
(−6.7–53.2)
ND 99.9
(99.7–100)
14.8*
(−22.1–40.6)
ND 97.2
(95.5–98.3)
98.9
(96.7–99.6)
Ctrl Netherlands Pooled Never −26.5*
(−72–7)
−17.2*
(−50.9–9)
4.6*
(−33–31.5)
−14.7*
(−50–12.3)
−6.3*
(−31.4–14)
−2.7*
(−41.5–25.5)
6.5*
(−19.4–26.9)
ND
ND: not done. Transmission-reducing activity is from duplicate SMFA experiments, with luminescence intensity 7–9 days after mosquito-feeding (using NF54HT-GFP-luc strain gametocytes) as the
output measure of infection intensity. All samples were tested in the presence of complement unless noted otherwise (C-). Total IgG represents the SMFA whole-purified patient IgG at physiological
concentration. Pure IgG represents the TRA of antibodies that bound to the R0.10c and 230CMB columns. Conc. IgG represents pure antibodies at 9 times the physiological concentration. The fractions
tested were as follows; 1. Total IgG, 2a. Purified α-R0.10c IgG, 2b. Concentrated (9×) α-R0.10C IgG, 3. Total IgG without α-R0.10c IgG, 4a. Purified α-230CMB IgG, 4b.Concentrated (9×) α-230CMB IgG,
5. Total IgG without α-R0.10C and α-230CMB-IgG. Fraction 5, depleted of antibodies binding to either protein column, was tested with and without (C-) complement. Ctrl is IgG from plasma from pooled
naive Dutch donors. All TR values and confidence intervals were calculated from two independent SMFAs with different culture material. TRA, CI and p-values were calculated using generalised linear
models (GLM) as described previously72. Asterisks (*) indicate results in which the oocyst/luminescence intensity of the test mosquitoes was not significantly different to the controls. Corrected ELISA
OD values for α-10c IgG in flow-through fractions: 1. A= 0.12, B= 0.88, C= 0.15, D = 0.08, E= 0.13, F= 0.08, Ctrl= 0.02; 3. Range for all individuals 0.01–0.04. Corrected ELISA OD values for α-
230CMB IgG in: 1. A= 0.05, B= 1.16, C= 0.76, D = 0.27, E= 0.10, F= 0.07, Ctrl= 0.06; 5. Range for all individuals 0.01–0.03
Anti-Pfs48/45
Wild-type Δ Pfs48/45
BF BFFITC FITC
Anti-Pfs230
Donor A
Total lgG
Donor A
Depleted lgG
Fig. 4 Gamete surface immuno-fluorescence assay (SIFA) using wild-type and Pfs48/45 knockout (KO) NF54 gametes, with Pfs48/45 mAb, Pfs230 mAb,
and IgG from a malaria-exposed serum donor. Donor IgG is from donor A in Table 2, and was performed using total IgG, and total IgG depleted of α-Pfs48/
45-10c and α-Pfs230 (230CMB) IgG. Δ Pfs48/45= Pfs48/45 KO3. BF Bright-field, FITC fluorescein isothiocyanate. Anti-Pfs48/45 is mAb 45.1, and anti-
Pfs230 is mAb 2A2, as described in the methods. Scale bar is 20 µm
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PfGEST is not retained on the gamete surface by 20 min after
erythrocyte egress in P. falciparum (Supplementary Fig. 5B).
Though two antibodies produced modest TRA in singlicate
SMFA experiments at 10 µg/mL (generalised linear mixed model
(GLMM): maximum 49.3% TRA, 95% CI: 31.0–62.8, p< 0.001),
this was not replicable and showed no improvement with
concentration (Supplementary Fig. 4). These data indicate that
though naturally acquired PfGEST Ab appear to be biomarkers of
TRA, there is no current evidence to support a mechanistic role in
TRA.
The 13 potentially surface expressed proteins were represented
by 39 targets on the microarray, of which 16 were statistically
significantly associated with TRA in the SMFA. Though antibody
responses to most gametocyte proteins decrease with age,
responses to these 16 targets shared a pattern more similar to
Pfs48/45 and Pfs230; breadth of response to these targets
increased with age (p = 0.007), whereas magnitude of response,
though highest in older individuals, showed no age-dependent
association (Supplementary Fig. 6). Gametocyte-positive indivi-
duals recognising ≥4/16 of these targets (4 being the 75th
percentile of breadth of response to these targets) showed lower
infectiousness (LogR: OR 0.36 (95% CI: 0.23–0.56), p< 0.001)
and infection rates (OR 0.32 (95% CI: 0.16–0.62, p = 0.001) in the
DMFA (Fig. 3a, b). These patterns remained significant when
Pfs48/45 or Pfs230 seropositive individuals were excluded
(infectiousness: LogR, OR 0.34 (95% CI: 0.20–0.58), p< 0.001;
infection rate: OR 0.31 (95% CI: 0.15–0.64), p = 0.001).
Discussion
In this study, we assessed antibody-mediated transmission-
reducing activity (TRA) in individuals naturally exposed to P.
falciparum and identified associated antibody responses. A
minority of samples (3.3%) demonstrated strong and repro-
ducible levels of TRA in controlled in vitro assessments with
cultured P. falciparum gametocytes; high-level TRA was asso-
ciated variably with antibody responses to gametocyte antigens
Pfs48/45, Pfs230 and 43 newly described proteins. These antibody
responses were associated with reduced mosquito infection rates
in feeding assays with local mosquito species on infected, game-
tocytaemic individuals. Although not all of the identified antibody
responses will be causally involved in TRA, we provide the first
direct evidence for independent roles of antibodies specific to
Pfs48/45 and Pfs230 in naturally acquired TRA. The TRA of mAb
specific to one of the novel TRA biomarkers, PfGEST, indicate
that PfGEST antibodies elicited by P. falciparum exposure are
likely to be non-functional biomarkers of TRA.
The transmission of P. falciparum to mosquitoes is influenced
by numerous factors, including gametocyte density60, sex ratio61
and human host factors that are currently poorly characterised. A
direct effect of naturally acquired antibodies on transmission
efficiency is suggested by the observation that mosquito infection
rates generally increase in mosquito-feeding experiments on
naturally infected gametocyte carriers when autologous plasma is
replaced by control serum62. Antibody responses to Pfs48/45 and
Pfs230, established target antigens for transmission-blocking
vaccines15,36, are naturally acquired upon gametocyte exposure
and have previously been statistically associated with TRA as
measured in the SMFA10,21–28. The strength of these associations
is variable and sometimes absent29; TRA is often observed in
individuals without measurable α-Pfs48/45 or α-Pfs230
antibodies10,23,25,28,30,31. We performed SMFA experiments on
purified IgG samples from 648 malaria-exposed donors and
confirm previous associations between TRA and α-Pfs48/45 (OR
4.4, 95% CI: 1.5–12.9) and α-Pfs230 antibodies (OR 7.9, 95% CI:
Table 3 Proteins with TRA-associated antibody responses
Biomarkers of TR immunity, and plausible or known gametocyte/gamete surface proteins (remaining biomarkers in Supplementary Data 5)
Gene ID Gene description TM SP Parasite stage Cellular component (homology/annotation)
PF3D7_0209000 6-cysteine protein (P230) 0 Y Gametocyte-specific Known gamete surface protein, complex with P48/45
PF3D7_1346700 6-cysteine protein (P48/45) 1 Y Gametocyte-specific Known GPI anchored gamete surface protein
PF3D7_0305300 Conserved Plasmodium membrane protein,
unknown function
11 Gametocyte
enriched, shared
Extracellular region, membrane (transmembrane
transporter)
PF3D7_1021100 Conserved Plasmodium protein, unknown
function
2 Gametocyte-specific Membrane
PF3D7_1038400 Gametocyte-specific protein (Pf11-1) 1 Gametocyte-specific Host cell cytoplasm, implicated in gamete egress
PF3D7_1107900 Mechanosensitive ion channel protein 5 Gametocyte
enriched, shared
Membrane
PF3D7_1143700 Conserved Plasmodium protein, unknown
function
1 Gametocyte
enriched, shared
Cytoplasm, membrane
PF3D7_1306500 MORN repeat protein, putative 10 Gametocyte
enriched, shared
N/A (MORN, unknown cell component)
PF3D7_1314500 Cop-coated vesicle membrane protein p24
precursor, putative
2 Y Asexual enriched,
shared
Integral component of membrane
PF3D7_1360500 Guanylyl cyclase beta (GCbeta) 21 Gametocyte
enriched, shared
N/A (GCbeta, unknown cell component)
PF3D7_1433200 Conserved Plasmodium protein, unknown
function
1 Gametocyte
enriched, shared
Integral component of membrane, plasma membrane
PF3D7_1449000 Gamete egress and sporozoite traversal
protein, putative (GEST)
0 Y Gametocyte-specific Endoplasmic reticulum, microneme, osmiophilic body,
implicated in gamete egress
PF3D7_1014300 Conserved protein, unknown function 8 Gametocyte
enriched, shared
Cytoplasm, membrane
PF3D7_1348000 Conserved Plasmodium protein, unknown
function
2 Gametocyte-specific Cytoplasm, microtubule
PF3D7_1324600 Conserved Plasmodium protein, unknown
function
3 Gametocyte-specific Cytoplasm, membrane
TM: Transmembrane domains (TMHMM: PlasmoDB, PMID1115261. Credits: Anders Krogh, Bjorn Larsson, Gunnar von Heijne, and Erik L.L. Sonnhammer), SP: Signal peptides (SignalP: PlasmoDB.
PMID15223320. Credits Bendtsen JD, Nielsen H, von Heijne G, Brunak S), Parasite stage: Gametocyte score category based on an analysis of previous gametocyte and asexual proteomic databases, as
indicated in methods53. Details in Supplementary Data 1 and 5, Predicted/known cellular component (homology): Gene ontological terms (curated or computed) from PlasmoDB version 28, or annotation
for previously characterised proteins. For proteins without annotation or predicted function/location, domain prediction based on protein homology is presented in square brackets where available
(HHPred protein prdomain prediction, The MPI bioinformatics Toolkit as an integrative platform for advanced protein sequence and structure analysis78)
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2.8–22.8). Using a unique sample set with transmission data from
DMFA from three endemic settings, we further provide the first
evidence that α-Pfs48/45 and α-Pfs230 antibodies are associated
with reduced transmission efficiency during natural infections.
Both the likelihood of infecting any mosquitoes and the pro-
portion of infected mosquitoes were significantly lower for indi-
viduals with α-Pfs48/45 and α-Pfs230 antibodies. For the first
time, we formally demonstrate that naturally acquired antibodies
to these gametocyte antigens can independently inhibit mosquito
infection after affinity purification.
Despite the important role of antibodies to these two pre-
fertilisation antigens, 45% of plasma donors with high-level TRA
had no measurable α-Pfs48/45 or α-Pfs230 antibodies, and we
observed significant levels of TRA after IgG from a selection of
donors was depleted of α-Pfs48/45 and α-Pfs230 antibodies. Our
affinity purification experiments were based on the binding of
antibodies to epitopes present in the Pfs48/45-10C and 230CMB
vaccine constructs, as the proteins’ complex conformational
structures so far preclude their production as full-length proteins.
We thus captured the most potent transmission-reducing anti-
bodies (Pfs48/45 epitopes 1–321,22,36, Pfs230 epitopes within the
C region15) but not necessarily all antibodies to these proteins.
Monoclonal antibodies against epitope 5, which would not bind
to the Pfs48/45-10C protein, have been associated with weak TR
activity63. However, given their lower efficacy and the immuno-
dominance of epitopes 1–3 in naturally immune sera21 it is highly
unlikely that α-Pfs48/45 antibodies to epitopes other than epi-
topes 1–3 would have contributed considerably to TRA. This is
also supported by the finding that antibodies to epitope 5 are only
observed in the presence of antibodies to epitopes 1–321. Because
all known α-Pfs230 antibodies are complement dependent64,65,
whereas TRA in the antibody-depleted fraction is complement
independent, a role for residual α-Pfs230 antibodies (responsive
to epitopes outside the aa. 444–730 region of Pfs230 represented
by the 230CMB product) is similarly unlikely. Crucially, IgG
depleted of antibodies to Pfs48/45 epitopes 1–3 recognised surface
antigens of a knockout parasite line that fails to express Pfs48/45
and Pfs230, formally demonstrating recognition of other target
antigens by immune sera. Our findings of TRA in the absence of
measurable α-Pfs48/45 or α-Pfs230 antibodies, together with
persisting recognition of gametes that do not express these two
proteins, and functional TRA after depleting IgG of antibodies to
these two targets, thus strongly suggest that responses to other
antigens may contribute to naturally acquired TRA.
Using a protein microarray, we aimed to identify whether
responses to other gametocyte targets were associated with TRA.
This array was enriched for putative gametocyte surface antigens
but surface expression or gametocyte specificity were not pre-
requisites for inclusion on the array. Our aim was to determine an
immune signature of TRA that could improve our understanding
of transmission efficiency from natural infections. We therefore
included markers of gametocyte exposure as well as general
markers of recent malaria infection. We observed that responses
to 43 proteins were statistically significantly associated with high-
level antibody-mediated TRA. Responses to these antigens were
strongly predictive of transmission efficiency from natural P.
falciparum infections with diverse gametocyte strains and locally
relevant mosquito species. Whilst further studies are needed to
assess the generalisability of this signature of TRA across endemic
settings, the strong association of our SMFA-based signature of
TRA with reduced transmission potential during natural infec-
tions is very promising. Future studies should aim to assess the
kinetics of antibody responses to these antigens and their asso-
ciation with TRA using longitudinal cohorts, with well-defined
clinical, parasitological and infectivity data.
The microarray proteins were produced in an Escherichia coli
based in vitro transcription–translation (IVTT) system. As con-
formation is not verified for all proteins, those requiring post-
translational modifications will likely not have been expressed in
their native conformation. This was exemplified by Pfs48/45 that
has a known complex structure36,66 and showed minimal reac-
tivity or discriminative power when printed on the array as an
IVTT product (Supplementary Data 3). This apparent dis-
advantage of the IVTT system will plausibly have affected our
results for other conformational proteins, so the list of proteins in
Table 3 (and Supplementary Data 5) must be treated as a ‘rule in’
rather than ‘rule out’ selection for proteins associated with
antibody-mediated TRA.
Among the proteins we identified as having TRA-associated
antibody responses, 13 novel proteins have sequence character-
istics suggestive of surface expression and may be targets of TRA.
Previous data indicate that two of the proteins found to be bio-
markers of TRA in our analysis, PfGEST and Pf11-1, were pre-
viously shown to have important roles in gamete egress from the
erythrocyte in mosquitoes58,59. Interestingly, Pf11-1 mAbs are
able to reduce transmission, possibly by disabling full gamete
egress[58]. Our SIFA data with humanised mAbs indicate that
PfGEST has no clear surface expression in P. falciparum 20 min
after activation, which may explain their lack of replicable TRA in
mosquito-feeding assays compared to similar concentrations of
α-Pfs230-specific mAb. As there is only a narrow window of
opportunity for α-Pf11-1 and α-PfGEST antibody binding during
gamete egress, activity against gamete surface proteins with roles
in fertilization is a more biologically plausible mode of antibody-
mediated TRA. Future experiments may identify which of the 13
other TRA-associated plausible antibody targets in Table 3 are
expressed at the gamete surface. Our findings identify the further
characterisation of functional and non-functional gametocyte
antibody responses in individuals with naturally acquired TRA as
a research priority. Although the prevalence of high-level TRA
decreases with age, an opposite trend is observed for the mag-
nitude and prevalence of antibodies to Pfs48/45 and Pfs230 and
to newly identified gametocyte antigens, in spite of their overall
association with TRA (Supplementary Fig. 6). A better char-
acterisation of these antibody responses in relation to functional
activity is needed and may include a detailed assessment of
antibody isotype, affinity and complement-binding activities.
Regardless of their functionality, our data indicate that pos-
session of antibody responses to a group of P. falciparum proteins
increases the likelihood of antibody-mediated transmission
inhibition. Combined with assessment of α-Pfs48/45 and α-
Pfs230, this signature of TR immunity may improve our under-
standing of natural malaria transmission dynamics.
Methods
Study participants. Serum was collected from individuals recruited to epide-
miological studies in Burkina Faso, Cameroon and the Gambia (Table 1), as well as
from Dutch migrants with a history of residence in P. falciparum malaria-endemic
regions, who reported having been diagnosed with clinical malaria infection.
Details of sample collection and recruitment criteria have been published for all
samples from individuals living in endemic areas, but are provided here as a
summary. Parasitological status was defined by microscopy acknowledging that
this lacks the sensitivity to detect many low-density infections; i.e., microscopy
negative samples were not treated as an unexposed control.
Cameroon. Samples (n = 140) were collected between 2011 and 2015 from indivi-
duals aged 5–16 years, during surveys at primary schools in the Mfou district, 30
km from Yaoundé. Data from these individuals have in part been presented
previously42,43, but the remainder were provided by Isabelle Morlais (IRD, Mon-
tpelier) without prior publication. Participants were primarily P. falciparum
gametocyte carriers identified among asymptomatic children by microscopical
screening. Gametocyte density (median (IQR) = 30 (16/80)/µL, among gametocyte
positives) was calculated against 1000 leucocytes, assuming a density of 8000
leucocytes per µL.
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Gambia. Samples (n = 226) were collected from individuals resident in Farafenni
and nearby villages, approximately 200 km east of Banjul, in 1992–199424,44, 1998
and 199945, 200146,47 and 200248. Individuals were aged 1–17 years at the point of
sampling. Participants were enroled if they were found to be asymptomatically
infected with malaria parasites, based either on the observation of gametocytes24,44,
or asexual parasites45–48 by microscopy. Gametocyte density (median (IQR) = 63
(10/390)/µL, among gametocyte positives) was either calculated by examination of
100 high powered fields, assuming that 1 gametocyte per field equated to 500/µL
(threshold of 5 gametocytes/µL) as in Greenwood & Armstrong 199167, or by
calculation against 1000 leucocytes, assuming a density of 8000 leucocytes per µL.
Burkina Faso. Samples were collected from residents in the villages of Laye and
Dapélogo (n = 192), ~30 km northeast and north of Ouagadougo, in the Central
Sudan savannah area37,40,41, and from residents of Soumousso and Dande (n = 33),
villages close to Bobo Dioulasso38,39. The age of study participants ranged from 1.8
to 74 years. Recruitment was either random37,41, or based on the observation of
gametocytes38–40 or asexual parasites40 by microscopy. Gametocyte density
(median (IQR) = 64 (32/128)/µL, among gametocyte positives) was calculated
against either 500 or 1000 leucocytes, assuming a density of 8000 leucocytes per µL.
Netherlands. Dutch individuals were recruited by clinical staff at Radboud uni-
versity medical centre in Nijmegen, the Netherlands, and had either recently
returned (< 6 months) from extended periods in endemic areas (n = 8) or had
returned more than a year before sampling (n = 49). Age ranged from 26–84 years.
Those who had returned more than a year before sampling had lived in areas with
endemic P. falciparum transmission for longer than 15 years and reported between
2 and >80 clinical malaria episodes during that time. For these individuals malaria
infection history was only available through verbal testimony, whereas 3 out of 8 of
the recently returned migrants had confirmed recent or current malaria infection.
Samples were all collected between 1994 and 2014. As detailed previously, sera
from some of these expatriates show strong and consistent TRA in the SMFA68.
All samples were collected after written informed consent was obtained from
participants and/or their parent(s) or guardian(s). Ethical clearance was provided
by the National Ethics Committee of Cameroon, the Gambian Government/
Medical Research Council Joint Ethics Committee, the Ethical Review Committee
of the Ministry of Health of Burkina Faso and the Centre MURAZ ethical review
committees, the London School of Hygiene & Tropical Medicine ethics committee
and by the Radboud University Medical Center ethical committee.
Sample preparation. For SMFA, IgG was purified from all plasma samples using
Protein G HP Spintrap (GE Healthcare, GE Uppsala, Sweden), and concentrated to
the original serum volume using Vivaspin 20 centrifugal concentration columns
(Sartorius AG, Goettingen, Germany) following the manufacturer’s instructions.
Antibody purification was only attempted for samples with sufficient serum
volume for duplicate SMFAs (180 µL). For the serological assays, an additional 30
µL of serum was retained if sample volume permitted. Because of the high serum
volumes necessary for the antibody depletion/purification experiments, these were
performed on only six samples with transmission-blocking antibodies. Three of
these six were processed by protein microarray. IgG for depletion/purification was
purified from 1mL of serum using protein G high performance affinity columns
(HiTrap™ Protein G HP 1mL, GE Healthcare, Uppsala, Sweden), and then
adjusted to the original serum volume for testing in the specific Pfs48/45 and
Pfs230 affinity columns using Vivaspin 20 centrifugal concentration columns
(Sartorius AG, Goettingen, Germany). Overall, 300 µL was immediately removed
for SMFA and serological assays, leaving 700 µL of total IgG at physiological
concentration for affinity column purification. Purification was repeated as
required to allow for antibody eluate concentration.
Direct membrane-feeding assay (DMFA). DMFA was performed during the
original studies for 498/579 individuals from endemic areas, as described in the
separate study protocols using identical glass mini-feeders54 (Coelen Glastechniek,
Weldaad, the Netherlands) and the same experimental protocol69. Of the 498
individuals with DMFA data, 494 had microscopy-based estimates of asexual and
gametocyte density; only gametocyte positives (n = 366) were used in our DMFA
analysis. All sites used colonies sourced from eggs caught in local water sources.
Colonies were of A. gambiae s.s. (>90%) (The Gambia24,44–48), A. coluzzii
(Cameroon42,43 and Bobo Dioulasso in Burkina Faso38,39) or a comprised a mix-
ture of A. coluzzii, A. gambiae s.s. and hybrid forms (other Burkina Faso
sites37,40,41). Locally adapted mosquito colonies from all sites are available upon
request. Data presented in the current manuscript are the proportion of infectious
individuals and percent of mosquitoes infected with oocysts after feeding on whole
blood69.
Standard membrane-feeding assay (SMFA). Mosquitoes used for the assess-
ment of antibody TRA in the SMFA were three to 5 day old female Anopheles
stephensi (Sind-Kasur Nijmegen strain)70, which were reared at 30 °C and 70–80%
humidity while exposed to a 12 h day/night cycle. Mature (stage IV-V) P. falci-
parum gametocytes (either NF5454, or transgenic NF54HT-GFP-Luc71, depending
on the preferred readout) were obtained from an automated tipper system
(0.3–0.5% gametocytes, 2% haematocrit) and prepared with packed red blood cells
as previously described9,54. Both gametocyte strains can be obtained from the MR4
Malaria Research and Reference Reagent Resource Center (https://www.
beiresources.org/MR4Home.aspx). For the preparation of mosquito blood meals
containing test antibodies, 90 μL of serum IgG was added to 90 μL of freeze-dried
foetal calf sera (FCS) and diluted into 35 μL human serum containing active
complement. This antibody/serum mix was added to the gametocyte/red blood cell
mix to a final volume of 270 μL, and kept at 37 °C until it was provided to mos-
quitoes in the membrane-feeding apparatus. Antibodies were therefore provided to
mosquitoes at ~0.66* their physiological concentration (assuming a 1:1 plasma/cell
ratio). Each SMFA run was performed to test up to 24 antibody samples simul-
taneously, including two control mosquito groups (against which the TRA of test
samples was calculated). For control samples 90 μL of freeze-dried FCS was dis-
solved in 90 μL milliQ and added to the same gametocyte/red blood cell mix (270
μL total volume) as was used for the other feeds the run.
Prior to blood feeding, male mosquitoes were separated from females by
aspiration. Unfed and partially fed female mosquitoes were removed from their
resting containers after blood feeding. Fully engorged mosquitoes were maintained
at 26 °C and 70–80% humidity. Mosquito infection status was determined
differently for the NF54 and NF54HT-GFP-luc parasite strains. For experiments
with the native NF54 strain, an average of 19.5 mosquitoes (range: 7–22) were
dissected at day 7 post infection (PI). Midguts were stained in 1% mercurochrome
and oocysts were counted by expert microscopists. For experiments with the
transgenic NF54HT-GFP-luc strain, mosquitoes were killed on day 8 PI by
freezing, and 20 were homogenised for each experiment in two pools of 10.
Mosquito homogenates were well mixed and three samples per pool were assayed
for bioluminescence by lysis, and addition of luciferase assay substrate using a
Luciferase assay kit (Luciferase assay system (E1501), Promega, USA), according to
the manufacturer’s instructions and as previously described9.
For experiments with the native NF54 strain, TRA was analysed as the percent
difference in oocyst number between test and control mosquitoes. For experiments
with the transgenic NF54HT-GFP-luc strain, TRA was calculated as the average
percent difference in luminescence intensity for two pools of 10 mosquitoes
between test and controls mosquitoes, as described9. TRA <0% was observed, but
was generally within the normal range due to natural variation in oocyst intensity
between mosquito groups. For individuals with TRA <0%, median TRA was
-41.8% (IQR: −80.9–16.5). For experiments with replication (e.g. the affinity
purification experiments) 95% CI around the TRA estimate were calculated from
luminescence or microscopical readouts for multiple feeds using generalised linear
mixed models (GLMMs)72. Choice of readout (and therefore of gametocyte strain)
varied over the time that the SMFA’s were being performed, and makes no
difference to the integrity or interpretation of TRA, only to its efficiency9. Overall,
≥90% reduction in oocyst/luminescence intensity in test mosquitoes relative to
controls was classified as evidence of high-level TRA, which previous data indicate
is highly replicable68. Samples from all individuals with ≥80% TRA were tested in
duplicate to ensure robustness of the functional phenotype and the mean value of
duplicate experiments was used to classify individuals as having high-level TRA
(≥90% average reduction) or no evidence of TRA (<10% average reduction).
Recombinant protein production for serological assays. Recombinant, correctly
folded proteins were used for antibody depletion/purification experiments and for
enzyme-linked immunosorbent assays (ELISA). For all assays assessing Pfs230-
specific antibodies, we used the transmission-blocking vaccine candidate 230CMB
(developed and purified by Fraunhofer USA Center for Molecular Biotechnology),
which corresponds to amino acids 444–730 of the Pfs230 protein, and comprises
the protein’s pro-domain and the first of fourteen cysteine motif domains15. For
assays with Pfs48/45, two protein constructs were used. For antibody depletion/
purification, we used the chimeric R0.10C protein36, which comprises 10 cysteines
spanning epitopes 1–3 of the Pfs48/45 C-terminal domain, fused to the GLURP R0
domain36,40. Antibodies specific to GLURP R0 have no effect on Plasmodium
transmission to mosquitoes (Supplementary Table 2)9. For non-functional ser-
ological assays (ELISA, Microarray), the 10C protein was cleaved from the R0.10C
as described previously40.
Monoclonal antibodies. SMFA data using mAb specific to GLURP R0, Pfs48/45
(85RF45.1), Pfs230 (2A2) and PfGEST are presented in Supplementary Fig. 4 and
Supplementary Table 2. Full details for GLURP R0 and Pfs48/45 (85RF45.1) mAb
production and SMFA is provided in Stone et al.9 Details of Pfs230 mAb pro-
duction and SMFA are presented in Roeffen et al. 199565. PfGEST mAbs were
produced by the Hypothesis-driven Pre-erythrocytic Antigen Target Identification
Consortium (HPATIC). Briefly, HKL v2.0 KymiceTM containing human variable
region genes (Kymab) were immunised with recombinant protein expressed in the
wheat germ cell-free system (CellFree Sciences) adjuvanted with Montanide ISA
720. Non-antigen selected splenocytes were sorted into 96 well plates, one cell/well,
to generate single-cell mRNA material (Atreca). Atreca’s Immune Repertoire
Capture (IRCTM) provides Single-Cell mRNA Barcode-Sequencing with high
throughput and accuracy. This platform captured full-length sequences, enabling
detection of somatic mutations across the entire antibody variable region. Natively
paired heavy and light chain IgG variable regions were analysed, and constant
region isotype assignments were made which were then produced via gene
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synthesis and recombinant expression as fully human antibodies (LakePharma).
Three mAbs were tested in duplicate SMFA titration experiments. SMFA was
conducted according to previously published protocols9. In all mAb-based SMFA,
the endpoint was oocyst quantification by manual dissection.
Pfs48/45 and Pfs230 antibody purification. To purify antibodies specific to the
Pfs48/45 and Pfs230 proteins from transmission-reducing sera, affinity columns
were created by coupling 1 mg of R0.10C or 230CMB to N-hydroxysuccinimide
(NHS)-activated high performance affinity chromatography columns (HiTrap™
NHS-activated HP 1mL, GE Healthcare, Uppsala, Sweden); coupling efficiency was
>80%.
For the extraction of antibodies from human serum, antibodies were extracted
first using the R0.10C column, and then using the 230CMB column, as follows. The
R0.10C column was equilibrated with 2 mL of binding buffer (PBS (1×) before 700
µL of total IgG (at physiological concentration, fraction 1 in Table 2) from
transmission-blocking sera was added. The flow-through was collected and the
column washed with 12 mL of PBS. Overall, 5 mL of elution buffer (0.15 M NaCl,
0.1 M glycine/HCL, pH 2.5) was applied to the column for the collection for
R0.10C-specific antibodies. After elution, the purification procedure was repeated
using the flow-through from the first purification, and the antibody eluates from
both runs were pooled. The final flow-through and combined antibody eluates
(fraction 2a in Table 2) were concentrated to 700 µL using Vivaspin 20 centrifugal
concentration columns (Sartorius AG, Goettingen, Germany). Overall, 300 µL of
the flow-through was removed for SMFA (fraction 3 in Table 2) and serological
assays, and the remaining 400 µL was processed over the equilibrated 230CMB
column as for the R0.10C column, except that the final flow-through’s (fraction 5
in Table 2) and eluates (fraction 4a in Table 2) were concentrated to 400 µL.
Depletion of specific antibody in the flow-through’s of each column was confirmed
with ELISA. Antibodies (from eluates or flow-troughs) were processed in the
SMFA in two biological replicates, as for total IgG with >80% TRA in the larger
SMFA screen. For three samples, larger starting volumes were used to allow
antibody eluates to be concentrated nine times, to examine the effect of specific
concentrated antibody on transmission-reducing activity (fractions 2b and 4b in
Table 2).
The possibility that TRA from the column fractions was due to cytokines or
reactive ROx/RNOx species, which in circumstances of inflammatory crisis can
inhibit parasite development in mosquitoes73, was excluded both by our use of
protein G binding columns for IgG purification for all samples, and our use of 30
kDa filters for antibody concentration prior to mosquito-feeding.
Surface immuno-fluorescence assays (SIFA). The Pfs48/45 KO NF54 P. falci-
parum line was produced and characterised by van Dijk et al3. and subsequently
assessed by Eksi et al.12 Eksi et al. showed that Pfs230 is produced but not retained
on surface of Pfs48/45 disruptant gametes. Wild-type (WT) and Pfs48/45 KO
gametocytes were generated using standard protocols, as described above. Culture
media Pfs48/45 KO line was supplemented with 2 µM pyrimethamine. Briefly,
gametocytes were allowed to activate at room temperature for 20 min (for mAb
SIFA) or 1 h (for human IgG SIFA) in the presence of foetal calf serum (FCS), and
gametes were prepared for microscopy by washing with PBS supplemented with
0.5% FCS and 0.05% sodium azide. Antibodies were added to gamete preparations
in the same PBS/FCS buffer; mAbs at 5 µg/mL; human IgG/sera at dilutions of 1:20.
Secondary antibodies were Alexa Fluor TM 488 goat anti-human IgG (H+L), Alexa
Fluor TM 488 chicken anti-mouse IgG (H+L), and Alexa Fluor TM 488 goat anti-
rat IgG (H+L); all were added at dilutions of 1:200. All gamete preparations were
incubated with secondary antibody at room temperature for 1 h.
ELISA. Antibodies specific to the Pfs48/45-10 C and Pfs230 (230CMB) proteins
were quantified in the ELISA exactly as described previously40. Optical density
(OD) values were normalised between assay plates by adjustment relative to a
consistent point in the linear portion of a standard curve of serially diluted highly
reactive human sera. Cut-offs for positivity were determined from normalised OD
values using maximum likelihood methods to define Gaussian populations of low
and high responders as described previously74. For Dutch migrants who had
returned from endemic areas ≥1 year before sampling, a seropositivity threshold
was calculated as the mean+3 standard deviations of the averaged normalised OD
values of eight naïve European control sera.
Protein microarray. The selection of proteins to be cloned and printed on the
arrays was made primarily based on observed expression by stage V P. falciparum
gametocytes in a single recent proteomic analysis52. To ensure that the array
included most potential antibody targets, we preferentially included proteins that
had transmembrane domains, signal peptides or GPI anchors. To ensure that the
majority of proteins that were highly abundant or ‘specific’ to mature gametocytes
were included on the array, we used mass spectrometry data from the analysis of
the stage V gametocyte proteome52, alongside proteomic data from purified tro-
phozoites1 and schizonts (Supplementary Data 6, PRIDE accession number:
PXD008250) generated in the same laboratory. Gametocyte and asexual stage-
specific expression data sets were generated in relative expression values to
compare protein abundances (label-free quantitative (LFQ) values) between the
stages, which are presented in Supplementary Data 1 as a fold-change value.
We chose to also include proteins that were potential markers of gametogenesis
identified by Silvestrini et al.1 These proteins we identified as being expressed
primarily by early gametocytes, or shared between stages (proteins for 32/59 were
present in the stage V database), but some were more abundant in mature
gametocytes or other parasite life stages (Supplementary Data 1). In addition to
these markers, we included four putative markers of asexual parasite exposure:
PF3D7_1036000 (Merozoite surface protein 11 (MSP11)), PF3D7_0711700
(erythrocyte membrane protein 1, PfEMP1 (VAR)), PF3D7_0731600 (acyl-CoA
synthetase (ACS5)), and PF3D7_0423700 (early-transcribed membrane protein 4
(ETRAMP4)), based on work by Helb et al.51
Details of the 315 proteins included on the array are given in Supplementary
Data 1. Proteins with reference sequences longer than 1000 amino acids were split
into multiple fragments (overlaps of at least 17 a.a) for cloning, in vitro protein
expression and printing. Because the basic criteria for the selection of proteins for
microarray construction was based on data generated from a single laboratory, we
cross-referenced our protein list against a cross-study analysis of gametocyte
specificity53. In short, the specificity of any protein for the gametocyte stage was
scored by determining how often it had been detected across 11 proteomic analyses
(listed in Supplementary Data 1: 3 of gametocytes only, 3 of asexual stages only,
and 5 of both asexuals and gametocytes). Proteins were binned from low to high
abundance and weighted according to the retrieval rates of proteins in two curated
lists of ‘gold standard’ gametocyte and asexual genes, consisting of genes that are
known to be specific for either asexual stages (n = 45) or gametocytes (n = 41). High
expression of gametocyte gold standard proteins with concurrent absence of non-
gametocyte gold standard proteins resulted in a high gametocyte score, calculated
from the fraction of retrieved gametocyte genes over retrieved non-gametocyte
genes. All scores were log-transformed and summed over all data sets. Gametocyte
scores were categorised using the scores’ distribution of the gametocyte gold
standard as follows: scores above the first quartile (9.69) were considered
gametocyte-specific. Proteins scoring at least as high as the lowest scoring
gametocyte gold standard representative (-2.46) were considered as enriched in
gametocytes. Proteins with lower scores are not specific to a certain life stage and
have some evidence for expression in gametocytes. All proteins scoring lower than
the median of the asexual gold standard (-18.98) were considered asexual specific.
This analysis confirmed that 228 of the 315 proteins had consensus evidence for
enrichment in gametocytes (scores >−2.46), whereas 284/315 had conservative
evidence for expression in gametocytes (peptides present in at least one gametocyte
proteomic database, score >−10). 312/315 were present in at least one gametocyte
proteomic database, giving rise to a score >−18.93. Scores for all proteins on the
array are included in Supplementary Data 1. To avoid further curation and
potential bias, no proteins were excluded prior to analysis.
Proteins were expressed using an in vitro transcription and translation (IVTT)
system, the Escherichia coli cell-free Rapid Translation System (RTS) kit (5 Prime,
Gaithersburg, MD, USA). A library of partial or complete CDSs cloned into a T7
expression vector pXI has been established at Antigen Discovery, Inc. (ADI, Irvine,
CA, USA). This library was created through an in vivo recombination cloning
process with PCR-amplified CDSs, and a complementary linearised expressed
vector transformed into chemically competent E. coli was amplified by PCR and
cloned into pXI vector using a high-throughput PCR recombination cloning
method described elsewhere50. Each expressed protein includes a 5′ polyhistidine
(HIS) epitope and 3′ hemagglutinin (HA) epitope. After expressing the proteins
according to manufacturer instructions, translated proteins were printed onto
nitrocellulose-coated glass AVID slides (Grace Bio-Labs, Inc., Bend, OR, USA)
using an Omni Grid Accent robotic microarray printer (Digilabs, Inc.,
Marlborough, MA, USA). Each slide contained eight nitrocellulose ‘pads’ on which
the full array was printed, allowing eight samples to be probed per slide. Microarray
chip printing and protein expression were quality checked by probing random
slides with anti-HIS and anti-HA monoclonal antibodies with fluorescent labelling.
Each chip contained 28 IVTT negative control targets (for data normalisation), and
48 IgG positive control targets (for quality control).
For analysis of antibody reactivity on the protein microarray, serum samples
were diluted 1:200 in a 3 mgmL−1 E. coli lysate solution in protein arraying buffer
(Maine Manufacturing, Sanford, ME, USA) and incubated at room temperature for
30 min. Chips were rehydrated in blocking buffer for 30 min. Blocking buffer was
removed, and chips were probed with pre-incubated serum samples using sealed,
fitted slide chambers to ensure no cross-contamination of sample between pads.
Chips were incubated overnight at 4°C with agitation. Chips were washed five
times with TBS-0.05% Tween 20, followed by incubation with biotin-conjugated
goat anti-human IgG (Jackson ImmunoResearch, West Grove, PA, USA) diluted
1:200 in blocking buffer at room temperature. Chips were washed three times with
TBS-0.05% Tween 20, followed by incubation with streptavidin-conjugated
SureLight P-3 (Columbia Biosciences, Frederick, MD, USA) at room temperature
protected from light. Chips were washed three times with TBS-0.05% Tween 20,
three times with TBS, and once with water. Chips were air dried by centrifugation
at 1000×g for 4 min and scanned on a GenePix 4300A High-Resolution Microarray
Scanner (Molecular Devices, Sunnyvale, CA, USA). Target and background
intensities were measured using an annotated grid file (.GAL).
Raw microarray protein target and local background fluorescence intensities,
target annotations and sample phenotypes were imported and merged in R
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(Foundation for Statistical Computing, Vienna, Austria), where all subsequent
procedures were performed. Foreground target intensities were corrected for local
background using the backgroundCorrect function of the limma package75. Next,
all corrected values were transformed using the base 2 logarithm. The data set was
normalised to remove systematic effects by subtracting the median signal intensity
of the IVTT controls for each sample. As the IVTT control targets carry the chip,
sample and batch-level systematic effects, but also antibody background reactivity
to the IVTT system, this procedure normalises the data and provides a relative
measure of the specific antibody binding to the non-specific antibody binding to
the IVTT controls (a.k.a. background). With the normalised data, a value of 0.0
means that the intensity is no different than the background, and a value of 1.0
indicates a doubling with respect to background.
Data analysis. Quality control plots were made after each treatment of the
microarray data, which included boxplots and density plots of probe intensity by
study sample and probe type. Recombinant Pfs230 CMB was printed on the array
for comparison to ELISA with the same protein, yielding a correlation co-efficient
(Spearman’s rank) of 0.44 (p< 0.001). A universal seropositivity threshold for
reactivity to array proteins was established as the IVTT background plus 3 standard
deviations, which equated to a log2-transformed signal intensity threshold of 0.92
(reactivity was therefore defined as approximately twice that of the background).
Because high-level transmission-reducing activity was uncommon in our sample
set (22/649 samples had TRA ≥90%), antigens were defined as ‘reactive’ if they
elicited seropositive responses in at least 1% of the study population (≥7 subjects),
and unreactive antigens were included in all analyses. The universal cut-off was
used only for defining proteins as reactive or unreactive, and for depicting antibody
breadth for all microarray proteins.
Statistical analysis was conducted using R (Foundation for Statistical
Computing, Vienna, Austria) or STATA 12 (StataCorp., TX, USA). The magnitude
of antibody reactivity to each antigen on the microarray by individuals in different
groups was tested by empirical Bayes-moderated t-tests76, and by logistic
regression after data binarisation using protein-specific cut-offs; cut-offs were
generated using maximum liklihoods methods (which determines the junction
between two Gaussian signal distributions for each protein that proteins cut-off
point for positivity)74. For the latter, proteins were dis-included from the analyses if
the mixture models failed to stably converge, or had to restart more than once. In
both the Bayes and logistic models, p-values were adjusted to control the false
discovery rate below 5% using the Benjamini–Hochberg (BH) method57, and a
finding was considered significant for FDR controlled p-values (q-values) <0.05.
For analysis of TRA on a continuous scale, TRA was used as the log-transformed
relative intensity, to normalise the data and avoid compression at 0%. For clarity,
figures presenting TRA on a continuous scale present the linear TRA with a base of
0%. Linear models with adjustment for gametocyte density (determined by
microscopy, and given as gametocytes/µL) were used to test for differences in
continuous variables between groups. Logistic models adjusted for gametocyte
density were used to test for the association of binary variables between groups,
presenting odd-ratios and 95% CI. Differences in the magnitude of response to all
proteins by groups of individuals (in contrast to the Bayes analysis, which
compares responses to individual proteins by different groups of individuals) were
assessed with t-tests or ANOVA. Differences in mosquito infection prevalence in
the DMFA were analysed with logistic models adjusted for gametocyte density,
while differences in mosquito oocyst prevalence were assessed with logistic models,
adjusted for gametocyte density and with host (individual the mosquitoes were
feeding upon) as a random effect. All boxplots are standard Tukey’s whisker and
boxplots, with Tukey’s method for outlier determination. All DMFA-based analysis
was performed on gametocyte-positive individuals only. Protein-domain
predictions for proteins with TRA-associated responses were made using Inter-
pro77 or HhPred protein-domain prediction78.
Data availability. The novel P. falciparum Schizont mass spectrometry proteomics
data have been deposited to the ProteomeXchange Consortium (http://
proteomecentral.proteomexchange.org) via the PRIDE partner repository79 with
the data set identifier PXD008250. The authors declare that all other data sup-
porting the findings of this study are available within the article and its Supple-
mentary Information, have been deposited in the DRYAD data depository (https://
doi.org/10.5061/dryad.8bp05), or are available from the authors upon request.
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